Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL

NEW YORK, March 28, 2017  -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it has enrolled the first participant in the Phase 3 HONOR study of TNX-102 SL 5.6 mg, for the treatment of posttraumatic stress disorder (PTSD).
 
"Enrolling the first participant in the HONOR study is an important event not only to Tonix, but potentially to millions who suffer worldwide from both civilian and military-related PTSD," said Seth Lederman, M.D., Tonix's president and chief executive officer. “The HONOR study is designed to confirm the clinical benefit of TNX-102 SL to improve PTSD symptoms across several measures as demonstrated in our Phase 2 AtEase study in military-related PTSD.”
Read more: Tonix Pharmaceuticals Holding Corp ( TNXP )

RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109

RXI-109 is a self-delivering RNAi compound (sd-rxRNA) in development to reduce dermal and ocular fibrosis
 
MARLBOROUGH, Mass., March 28, 2017  -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today announced that it was granted a patent from the Japan Patent Office (JPO) for the composition of matter of sd-rxRNAs targeting connective tissue growth factor (CTGF) for the treatment or prevention of fibrotic disorders, including but not limited to skin fibrosis and proliferative retinopathy (Japanese Patent #: 6060071).  This patent includes the Company's lead clinical candidate RXI-109, an sd-rxRNA therapeutic compound, which is currently being evaluated in Phase 2 clinical trials. The patent, once issued, will be set to expire in 2031.
Read more: RXi Pharmaceuticals ( RXII )

Catalyst Biosciences Announces IND Approval in South Korea for Next-Generation Subcutaneous Factor IX Program

-- Investigational New Drug (IND) approval from Korean Ministry of Food and Drug Safety represents a key milestone in Catalyst’s Factor IX development program ------ Catalyst’s collaborator, ISU Abxis, plans to initiate a Phase 1/2 proof-of-concept study in individuals with severe hemophilia B in the second quarter of 2017 --
 
SOUTH SAN FRANCISCO, Calif., March 28, 2017  -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the Korean Ministry of Food and Drug Safety (MFDS) approved the Investigational New Drug Application (IND) for CB 2679d/ISU304. Hemophilia is a serious bleeding disorder that results in spontaneous bleeding episodes as well as substantially prolonged bleeding times upon injury.
Read more: Catalyst Biosciences ( CBIO )

Live Testing with Cannabix Marijuana Breathalyzer Shows Excellent Sensitivity for THC and Related Metabolites

The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety
 
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 27, 2017) - Cannabix Technologies Inc. (CSE:BLO)(CSE:BLO.CN)(OTC PINK:BLOZF) (the "Company or Cannabix") developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to announce that preliminary human subject testing during the month of March have produced excellent results. Cannabix is developing its FAIMS- (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer for the detection of delta-9-tetrahydrocannabinol ("THC") in human breath. Testing using the Cannabix Marijuana Breathalyzer Beta prototype device with human subjects after smoking THC cigarettes demonstrated the successful detection of THC, the psychoactive component of marijuana, in real-time. In addition to THC, several metabolites were identified in the breath of the human subjects including 11-hydroxy-delta-9-tetrahydrocannabinol and delta-9-carboxy-tetrahydrocannabinol, and three other cannabinoids related to cannabigerol, were confirmed by mass spectrometry after the inhalation of cannabis.
Read more: Cannabix Technologies ( BLO )

Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501

- Oral administration of MAT2501 at all tested doses yielded blood levels that were well below the labeled safety limits recommended for IV-administered amikacin -
- MAT2501 was well-tolerated with no serious adverse events observed -
 
BEDMINSTER, N.J., March 27, 2017 -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today reported positive topline data from its Phase 1 single-ascending dose study of MAT2501 in healthy volunteers.   
 
MAT2501 is Matinas BioPharma’s orally-administered formulation of the broad spectrum IV-only aminoglycoside antibiotic agent amikacin, which utilizes the Company’s proprietary lipid-crystal nano-particle cochleate delivery technology. 
Read more: Matinas BioPharma Holdings ( MTNB )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker